Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors by Kloth, J.S.L. (Jacqueline) et al.
Incidence and relevance of QTc-interval
prolongation caused by tyrosine kinase
inhibitors
J S L Kloth*,1,9, A Pagani2,9, M C Verboom3, A Malovini4, C Napolitano5, W H J Kruit1, S Sleijfer1,6, N Steeghs7,
A Zambelli8 and R H J Mathijssen1
1Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3075EA Rotterdam, The Netherlands;
2Department of Medical Oncology, Fondazione S. Maugeri, Via Maugeri 10, 27100 Pavia, Italy; 3Department of Clinical Oncology,
Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands; 4Laboratory of Informatics and Systems
Engineering for Clinical Research, Salvatore Maugeri Research and Care Institute, Pavia, Italy; 5Department of Molecular
Cardiology, IRCCS Fondazione S. Maugeri, Via Maugeri 10, 27100 Pavia, Italy; 6Cancer Genomics Netherlands, Amsterdam,
The Netherlands; 7Department of Medical Oncology, Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam,
The Netherlands and 8Department of Medical Oncology, Ospedale Papa Giovanni XXIII, P.zza OMS n 1, 24127 Bergamo, Italy
Background: Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram
(ECG). The QTc-interval prolongation increases the risk of life-threatening arrhythmias. However, studies evaluating the effects of
TKIs on QTc intervals are limited and only consist of small patient numbers.
Methods: In this multicentre trial in four centres in the Netherlands and Italy we screened all patients who were treated with any
TKI. To evaluate the effects of TKIs on the QTc interval, we investigated ECGs before and during treatment with erlotinib, gefitinib,
imatinib, lapatinib, pazopanib, sorafenib, sunitinib, or vemurafenib.
Results: A total of 363 patients were eligible for the analyses. At baseline measurement, QTc intervals were significantly longer in
females than in males (QTcfemales¼ 404ms vs QTcmales¼ 399ms, P¼ 0.027). A statistically significant increase was observed for the
individual TKIs sunitinib, vemurafenib, sorafenib, imatinib, and erlotinib, after the start of treatment (median DQTc ranging from
þ 7 to þ 24ms, Po0.004). The CTCAE grade for QTc intervals significantly increased after start of treatment (P¼ 0.0003).
Especially patients who are treated with vemurafenib are at increased risk of developing a QTc ofX470ms, a threshold associated
with an increased risk for arrhythmias.
Conclusions: These observations show that most TKIs significantly increase the QTc interval. Particularly in vemurafenib-treated
patients, the incidence of patients at risk for arrhythmias is increased. Therefore, especially in case of combined risk factors, ECG
monitoring in patients treated with TKIs is strongly recommended.
Long QT syndrome (LQTS) is a myocardial repolarisation disorder
characterised by prolongation of the QT interval on the surface
electrocardiogram (ECG). The clinical presentation of LQTS consists
of palpitations, syncope, seizures, and sudden cardiac death due to
a characteristic arrhythmia known as torsades de pointes (TdP)
(El-Sherif and Turitto, 2003; Moss, 2003; Trinkley et al, 2013).
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The QT interval represents the total duration of ventricular
depolarisation and repolarisation. It is measured on the ECG from
the first deflection of the QRS complex to the end of the T-wave.
Prolongation of the QT interval usually results from delayed
repolarisation. This can be caused by drugs or inherited ion
channel abnormalities, which block or result in loss of function of
potassium channels (IKr, IKs, and IKl), or opening or gain of
function of sodium (Ina) or calcium channels (Grant, 2009). The
QT interval is usually corrected for heart rate, leading to the
corrected QT interval QTc.
Several factors such as gender, age, electrolyte disturbances,
cardiovascular diseases (CVD), and different types of drugs can
affect the duration of the QT interval (Yetkin et al, 2001; Benoit
et al, 2005). Due to the risk of fatal arrhythmias, the US Food and
Drug Administration (FDA) now requires thorough studies to
evaluate the potency of new drugs to induce QT-interval
prolongation in preclinical and early phase I clinical trials in
healthy individuals (El-Sherif and Turitto, 2003). However, for new
anticancer drugs these studies are usually not performed in healthy
individuals because of their toxicity profile (Curigliano et al, 2008;
de Jonge and Verweij, 2008).
As with many drugs, tyrosine kinase inhibitors (TKIs) are
reported to prolong the QT interval (Strevel et al, 2007; Bello et al,
2009; Lee et al, 2010; Tolcher et al, 2011; Dogan et al, 2012;
Doherty et al, 2013; Dong et al, 2013; Heath et al, 2013; Shah et al,
2013). In vitro studies demonstrated that lapatinib and imatinib
interact with the phosphorylation of the cardiac hERG channel.
This results in a reduction of the repolarising current (IKr), which
can lead to action potential prolongation and subsequent QT-
interval prolongation (Lee et al, 2010; Dong et al, 2013).
In a small prospective clinical study to evaluate the cardiac
safety of lapatinib in 21 patients, a mean QTc increase of 8.63ms
was seen (Dogan et al, 2012). In three prospective post-marketing
studies in patients with solid tumours treated with sorafenib
(N¼ 31), pazopanib (N¼ 48), and sunitinib (N¼ 24) a modest
increase of 9.0ms of QTc interval with the use of sorafenib, 4.4ms
after start of pazopanib and 9.6ms after start of sunitinib was seen
(Bello et al, 2009; Tolcher et al, 2011; Heath et al, 2013).
These drugs have been approved by the FDA because they
appear highly effective in situations where treatment options are
limited. With an increasing number of TKIs on market, a relatively
long on-treatment time, and the application in the adjuvant setting,
which is already standard for imatinib in patients with localised
GIST with a high risk of relapse, and which is being explored for
other TKIs in various tumour types, thorough QTc studies in this
group of drugs are necessary to get more insight into their cardiac
safety. In this multicentre study performed in four centres in the
Netherlands and Italy, we describe the incidence and relevance of
QTc-interval prolongation in patients with cancer treated with
different types of TKIs.
PATIENTS AND METHODS
Study design. We undertook a retrospective study in patients with
solid malignancies, who were treated with any type of TKI. Patients
from four centres in the Netherlands (Erasmus MC Cancer
Institute, Rotterdam, Leiden University Medical Centre, Leiden,
and Netherlands Cancer Institute—Antoni van Leeuwenhoek,
Amsterdam) and Italy (Salvatore Maugeri Foundation, Pavia) were
included.
This study was reviewed and approved by the Erasmus MC
Medical Ethical Board (MEC 2013-148). All ECGs were obtained
as standard clinical care. Demographic and clinical characteristics
of the analysed cohort were collected using clinical record forms
designed for this study.
Patients were considered eligible if they were aged X18 years,
were treated for solid tumours with any type of TKI and if at least
one ECG before start of TKI treatment and one ECG during
treatment with TKI were available. Exclusion criteria were as
follows: ECGs that do not match criteria for accurate QTc-interval
measurements (intra-ventricular conduction delay and/or pace-
maker driven rhythm), missing ECGs at baseline or during
therapy, and patients with a time-lapse between baseline ECG and
start of TKI treatment of more than 1 year. Patients who were
subsequently treated with different TKIs were included once. All
standard 12-lead ECGs analysed in this study were reviewed by a
single expert cardiologist (CN). The QT interval was measured
from the beginning of the QRS complex until the point where the
deflection of the T wave crosses the iso-electric line. A description
of the statistical method is presented in the Supplementary Material.
Definition of QTc prolongation. Since increases in heart rate
result in shortening of the QT interval, a correction for heart rate
was applied using the Bazett formula (Sagie et al, 1992):
QTc ¼ QT= RRp
In this formula, RR is the interval between two subsequent R
waves. The Bazett formula is the most frequently applied
correction in clinical practice, leading to the corrected QT interval
or QTc interval (Sagie et al, 1992).
A prolonged QT interval is associated with an increased risk of
polymorphic ventricular tachycardia, torsade de pointes (TdP).
This study defined a prolonged QT interval corrected for heart rate
(QTc) as X470ms, which represents o0.5% of the healthy
population (Kobza et al, 2009) and has been shown to be associated
with an increased risk of TdP (Trinkley et al, 2013). A clinically
relevant increase in QTc (DQTc) was defined as an increase of
X30ms between a patient’s baseline and subsequent ECG as this
has also been shown to be associated with increased risk (Li et al,
2010). The QTc was also categorised according to the Common
terminology criteria for adverse events (CTCAE) guidelines version
4.03 (grade 0, QTco450; grade 1, QTc 450–479ms; grade 2, QTc
480–499ms; grade 3, QTcX500ms; grade 4, QTcX500ms with
life-threatening signs or symptoms; grade 5, death). Relevant CVD
was defined as myocardial infarction and/or heart failure.
Outcome measures used in this study were (i) the quantitative
difference in QTc interval between on therapy and baseline ECG
measurements (DQTc, ms), (ii) the transition from a condition of
normal repolarisation to a condition in which QTc is prolonged to
an extent with high risk of arrhythmia as a consequence of the TKI
therapy (i.e., from QTco470 to QTcX470ms) (Kobza et al, 2009;
Trinkley et al, 2013), (iii) clinically relevant DQTc (defined as
DQTcX30ms, above which the risk for TdP is significantly
increased) (Li et al, 2010) and (iv) QTc-interval CTCAE grade
increase during TKI therapy.
RESULTS
Patient characteristics. A total of 1933 cases of TKI use were
screened in this study. In 644 cases at least one ECG before
treatment and one ECG during treatment were available. Among
these cases, 18 patients were included twice, with subsequent use of
different TKIs. One patient had a pacemaker-driven rhythm. In
262 patients, the time lapse between baseline ECG and start of
treatment was more than 1 year and patients were therefore
excluded from the analysis. The remaining study cohort consisted
of 363 patients. The median age at start of treatment was 60 years
(interquartile range (IQR) 51–67), and 59% of patients were male.
Sunitinib was the most frequently used TKI in our study cohort,
with a total of 110 treated patients. The median QTc interval at
baseline visit was 401ms (IQR 388–415), where 346 patients
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(95.3%) had a normal QTc interval (CTCAE grade 0), 14 (3.9%)
had grade 1, 2 patients (0.6%) had grade 2, and 1 patient (0.3%)
had a grade 3 QTc interval. A total number of 37 patients (10.2%)
had a known history of relevant CVD, while 34 patients (9.4%)
used co-medication, that can lead to QTc-interval prolongation
(Strevel et al, 2007). Patients’ demographics and disease character-
istics are presented in Table 1.
Variables modulating QTc interval at baseline visit. At baseline
measurements, QTc was slightly, but significantly greater in
females than in males (QTcfemales¼ 404ms (IQR 392–417) vs
QTcmales¼ 399ms (IQR 385–414), P¼ 0.027), which is consistent
with previous studies (Strevel et al, 2007). Patients treated with
co-medication known to prolong the QTc interval, such as anti-
depressants, anti-epileptics, and anti-emetics, had a statistically
significant higher baseline QTc interval than the patients who did
not use such co-medication (409ms (IQR 398–424) vs 400ms
(IQR 387–414), respectively, P¼ 0.035). Consistent with previous
studies, patients suffering from hypokalaemia had longer median
QTc intervals than patients with normokalaemia and hyperkalaemia
(median QTc in hypokalaemic, normokalaemic, and hyperkalaemic
patients 416ms (IQR 376–431), 401ms (IQR 389–415), and
391ms (IQR 381–408), P¼ 0.028, respectively). A more detailed
report about baseline QTc intervals according to the evaluated
variables is found in Supplementary Table 1.
Quantitative variations of the QTc interval. The median on
treatment time before the ECG was performed was 43 days (IQR
26–118 days). In the entire population of 363 patients, the start of a
TKI resulted in a statistically significant increase in QTc interval,
with a median DQTc of þ 11ms (Po0.00001). The distribution of
DQTc was significantly different across TKIs (P¼ 0.0001). When
analysing subgroups of patients treated with specific TKIs, patients
treated with sunitinib (N¼ 110), vemurafenib (N¼ 67), sorafenib
(N¼ 52), imatinib (N¼ 41), and erlotinib (N¼ 21) showed a
statistically significant increase in QTc interval after start of
treatment (median DQTc ranging from þ 7 to þ 24ms, Po0.004;
Figure 1). For lapatinib (N¼ 16) and pazopanib (N¼ 46), no
statistically significant increase in QTc interval after start of
treatment was found (Table 2).
Increase in CTCAE grade and prevalence of high-risk patients.
A statistically significant increase in CTCAE grade for QTc
intervals was observed after start of TKI therapy in the whole
cohort (P¼ 0.0003). In detail, 33 patients (9.1%) were charac-
terised by an increased CTCAE grade. Of these, 31 passed from
grade 0 to gradeX1, while the remaining 2 individuals passed from
grade 1 to grade 2 or 3. Of the remaining patients, 321 (88.4%) did
not have an increase or decrease in CTCAE grade after start of TKI
treatment, while 9 patients (2.5%) had a reduced CTCAE grade for
QTc interval (Table 3).
Similarly, a statistically significant increase in the prevalence of
high-risk patients was observed after TKI therapy start (QTcbaseline
X470ms¼ 1.7% vs QTctherapyX470ms¼ 5.8%, P¼ 0.005), with
20 individuals (5.5%) who transitioned from a low-risk to a high-
risk condition. Moreover, 5 patients (1.4%) developed QTcX500
ms (CTCAE grade 3) after therapy start, and 76 patients (20.9%)
experienced a clinically relevant QTc increase after TKI start. All
five patients who developed QTcX500ms after start of therapy
had a DQTc of X100ms.
When focusing on specific TKI subgroups, we observed that
individuals treated with vemurafenib (N¼ 67) were characterised
by a statistically significant increase both in terms of CTCAE grade
for QTc intervals (P¼ 0.008) and in the probability of becoming
Table 1. Patient characteristics
Variable N (%) or median (IQR)
Gender
Male 215 (59)
Female 148 (41)
Age (years) 60 (51–67)
QTc-interval baseline 401 (388–415)
QTc-interval therapy 415 (397–431)
Tumour type
RCC 101 (27.8)
GIST 49 (13.5)
HCC 45 (12.4)
Lung cancer 27 (7.4)
Breast cancer 16 (4.4)
Melanoma 69 (19.0)
Other 56 (15.4)
Type of TKI
Sunitinib 110 (30.3)
Vemurafenib 67 (18.5)
Sorafenib 52 (14.3)
Pazopanib 46 (12.7)
Imatinib 41 (11.3)
Erlotinib 21 (5.8)
Lapatinib 16 (4.4)
Gefitinib 10 (2.8)
WHO PS baseline
0 155 (42.7)
1 195 (53.7)
2 12 (3.3)
3 1 (0.3)
CVD 37 (10.2)
QTc co-medications 34 (9.4)
Race
Caucasian 349 (96.1)
Other 14 (3.5)
Site
EMC 184 (50.7)
NKI 118 (32.5)
LUMC 54 (14.9)
SMF 7 (1.9)
Abbreviations: CVD¼ cardiovascular disease; EMC¼Erasmus MC—Cancer Institute;
GIST¼gastro-intestinal stromal tumour; HCC¼hepatocellular carcinoma; LUMC¼ Leiden
University Medical Centre; NKI¼Netherlands Cancer Institute—Antoni van Leeuwenhoek;
RCC¼ renal cell cancer; SMF¼ Salvatore Maugeri Foundation; TKI¼ tyrosine kinase
inhibitor; WHO PS¼World Health Organisation performance score.
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Figure 1. DQTc in the whole cohort and in specific TKIs. Blue bars
represent the median baseline QTc interval and red bars represent the
median QTc interval during treatment. At the y axis, the QTc interval is
expressed in ms.
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high-risk patients (P¼ 0.023), also showing the greatest probability
of clinically relevant QTc increase (34.3%). No statistically
significant variations in the evaluated outcomes were observed in
the other TKI subgroups.
Characterisation of TKI-induced QTc variability. The median
age of patients who had a worsening of the CTCAE grade for QTc
interval was significantly higher than that of patients who did not
(62 years (IQR 59–72) vs 60 years (IQR 51–67), respectively,
P¼ 0.023). These patients also more often suffered from
hypokalaemia (20.7% vs 3.1%, P¼ 0.0009; Table 4). Multivariate
logistic regression confirmed that age and hypokalaemia were
independent predictors of worsened CTCAE grade for QTc
interval (OR¼ 1.10, 95% CI¼ 1.05–1.16, P¼ 0.0002 and
OR¼ 10.30, 95% CI¼ 2.22–4.64, P¼ 0.002).
Similarly, patients who had QTc prolongation toX470ms after
start of TKI treatment were significantly older than patients who
did not (66 years (IQR 60–76) and 60 years (IQR 51–66),
respectively, P¼ 0.007) and were more frequently treated with
QTc-prolonging co-medication (25% vs 8.5%, P¼ 0.030). This was
confirmed by multivariate logistic regression (OR¼ 1.10, 95%
CI¼ 1.04–1.15, P¼ 0.0004 and OR¼ 4.38, 95% CI¼ 1.14–15.25,
P¼ 0.023).
We did not identify variables that have a statistically significant
impact on quantitative DQTc or on the probability of clinically
relevant DQTc (Supplementary Table 2).
DISCUSSION
We found a significant increase in QTc intervals after start of
treatment with sunitinib, vemurafenib, sorafenib, imatinib, and
erlotinib. In most cases, the increase in QTc interval is only modest
and under normal conditions not clinically relevant. However, in
76 of the 363 patients the start of TKI treatment resulted in a
clinically relevant increase of the QTc interval of X30ms. The
incidence of high-risk patients, defined as QTcX470ms (Trinkley
et al, 2013), increased during treatment with a TKI. Still, only the
subgroup receiving vemurafenib showed a statistically significant
increase in the number of patients with QTc4470ms.
In the entire cohort, 21% of patients showed a clinically relevant
increase in QTc ofX30ms with TKI treatment, but as most had a
normal baseline QTc interval, only 5% had a QTc of X470ms,
which is associated with increased risk of arrhythmias. Although
older patients, patients with low potassium and patients taking co-
medication which can prolong the QTc interval are at higher risk
of QTc-interval prolongation, it is still not possible to differentiate
which patient is at risk at the start of treatment.
Therefore, treating physicians should anticipate this possible
increase in QTc intervals and perform ECGs during treatment with
TKI, and be aware of symptoms, such as palpitation, seizures, and
collapse, which may be the result of drug-induced LQTS. In those
diseases where alternative treatment is available, such as in
metastatic renal cell carcinoma where sunitinib and pazopanib
have equivalent efficacy (Motzer et al, 2013), consideration should
be given to use a TKI with less QTc prolongation effects if the QTc
is prolonged at baseline or develops during treatment.
Furthermore, many patients use co-medication during TKI
treatment. As drugs of a broad variety are known for drug-induced
QTc-interval prolongation, it is likely that patients use several
drugs which can lead to QTc-interval prolongation and thereby
intensifying the effect on the QTc interval. This was shown in this
study, where 14 patients (4%) using such co-medication were more
likely to develop QTc prolongation. In those cases, extra awareness
may be necessary and switching to drugs that are not likely to have
an effect on QTc interval should be considered.
This study has several limitations. This was a retrospective study
in patients treated with cancer, and therefore in most cases ECGs
were not performed at predefined times before, during, and after
TKI therapy. Since fluctuations in QTc interval are frequent and
may be caused by many factors (Yetkin et al, 2001; Benoit et al,
2005), this is a weakness of our study, and may have influenced
outcome (Molnar et al, 1996). Also, only patients treated with a
Table 2. TKI-induced change in QTc interval
QTc interval (ms)
Median (IQR)
TKI n Baseline Therapy P-value
Whole 363 401 (388–415) 415 (397–431) o0.00001
Sunitinib 110 393 (380–410) 406 (390–424) o0.00001
Vemurafenib 67 401 (394–417) 427 (415–442) o0.00001
Sorafenib 52 400 (386–412) 410 (394–425) 0.0004
Pazopanib 46 402 (390–411) 412 (395–431) 0.079
Imatinib 41 410 (396–424) 425 (410–439) 0.002
Erlotinib 21 412 (398–430) 421 (414–440) 0.004
Lapatinib 16 413 (405–423) 414 (397–428) 0.982
Gefitinib 10 403 (396–417) 409 (390–429) 0.919
Abbreviations: IQR¼ interquartile range; n¼number of patients within each TKI group;
DQTc¼median difference between QTc interval during TKI treatment and QTc interval at
baseline; TKI¼ tyrosine kinase inhibitor. Bold values are statistically significant.
Table 3. Increase in CTCAE grade and prevalence of high-risk patients
Change in CTCAE Grade after start of therapy QTcX470
TKI N
DQTcX30 ms
N (%)
Increased
N (%)
Unchanged
N (%)
Reduced
N (%) P-value
Baseline
N (%)
Therapy
N (%) P-value
Whole 363 76 (20.9) 33 (9.1) 321 (88.4) 9 (2.5) 0.0003 6 (1.7) 21 (5.8) 0.005
Sunitinib 110 22 (20.0) 4 (3.6) 104 (95.6) 2 (1.8) 0.746 1 (0.9) 3 (2.7) 0.617
Vemurafenib 67 23 (34.3) 9 (13.4) 58 (86.6) 0 (0) 0.008 1 (1.5) 8 (11.9) 0.023
Sorafenib 52 11 (21.2) 6 (11.6) 45 (86.6) 1 (1.9) 0.073 1 (1.9) 2 (3.9) 1
Pazopanib 46 6 (13.0) 3 (6.5) 41 (89.1) 2 (4.4) 0.410 1 (2.2) 2 (4.4) 1
Imatinib 41 8 (19.5) 5 (12.2) 34 (82.9) 2 (4.9) 0.430 1 (2.4) 1 (2.4) 1
Erlotinib 21 3 (14.3) 3 (14.3) 18 (85.7) 0 (0) 0.174 0 (0) 2 (9.5) NA
Lapatinib 16 1 (6.3) 1 (6.3) 14 (87.5) 1 (6.3) 1 1 (6.3) 1 (6.3) 1
Gefitinib 10 2 (20.0) 2 (20.0) 7 (70.0) 1 (10.0) 0.423 0 (0) 2 (20.0) NA
Abbreviations: CTCAE¼ common terminology criteria for adverse events; N¼ number of patients; NA¼ not applicable; TKI¼ tyrosine kinase inhibitor; DQTc¼difference between QTc interval
during TKI treatment and QTc interval at baseline measurement. Bold values are statistically significant.
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TKI were included and there was no control group given non-TKI
treatment in which the variation in the QTc interval could be
examined. Furthermore, there may be a bias in patient selection
since patients with cardiac events may be more likely to have had
ECGs performed. Patients who died from arrhythmia may not
have been included in analyses when no ECGs were available. One
patient taking a TKI in the study died suddenly. This did not occur
in a hospital and no cause of death was reported so it is unknown
whether this was related to QTc-interval prolongation. Possible
effects from electrolyte disorders on the QTc interval may have
been missed, because of missing data. However, we showed in a
large group of patients treated with TKIs that there is an overall
increase in QTc interval after start of treatment, which may
possibly be harmful for patients treated with these drugs. Future
prospective studies could improve the current knowledge about
TKI-induced QTc prolongation.
Overall, we may conclude that most TKIs tend to cause an
increase in QTc intervals. In some cases, this increase is clinically
relevant, and therefore the QTc interval should be verified in
patients before starting TKI treatment and during therapy.
Monitoring QTc intervals during TKI treatment is particularly
important in patients with a history of QTc-interval prolongation,
in patients using co-medication which can prolong the QTc
interval, in patients with electrolyte disorders, and in patients with
pre-existing CVD. Furthermore, during treatment with TKIs
physicians should be aware of clinical symptoms, which may be
attributed to QTc-interval prolongation.
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Ca2þ
Normo/Hyper 169 13 (61.9) 156 (71.6) 0.451 8 (80) 161 (70.3) 0.728
Hypo 70 8 (38.1) 62 (28.4) 2 (20) 68 (29.7)
Kþ
Normo/Hyper 304 23 (79.3) 281 (96.9) 0.0009 16 (88.9) 288 (95.7) 0.204
Hypo 15 6 (20.7) 9 (3.1) 2 (11.1) 13 (4.3)
Abbreviations: Ca2þ ¼ calcium level at time of QTc measurement during treatment; CVD¼ cardiovascular disease; CTCAE, common terminology criteria for adverse events; DM¼diabetes
mellitus; IQR, interquartile range; Kþ , potassium level at time of QTc measurement during treatment; N, number of analysed patients with non-missing values; TKI, tyrosine kinase inhibitor.
Bold values are statistically significant.
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